Ipsen Announces Its Corporate Agenda for 2017
PARIS–(BUSINESS WIRE)– Ipsen (Euronext: IPN; ADR: IPSEY) announced today its corporate agenda* for 2017:
| 23 February 2017: | Full year 2016 sales & results | ||
| 27 April 2017: | First quarter 2017 sales | ||
| 7 June 2017: | General shareholders’ meeting | ||
| 13 June 2017: | Payment of 2016 dividend** | ||
| 27 July 2017: | First half 2017 sales & results | ||
|
26 October 2017: |
First nine months 2017 sales | ||
* This financial calendar is for indicative purposes only and the Group could change its publication dates should it deem it necessary
** Pending approval of the Board of directors (22 February 2017) and of the General shareholders’ meeting (7 June 2017)
About Ipsen
Ipsen is a global specialty-driven pharmaceutical group with total sales exceeding €1.4 billion in 2015. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its fields of expertise cover oncology, neurosciences and endocrinology (adult & pediatric). Ipsen’s commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer and neuro-endocrine tumors. Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen’s R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis/Paris-Saclay, France; Slough/Oxford, UK; Cambridge, US). In 2015, R&D expenditure totaled close to €193 million. The Group has more than 4,600 employees worldwide. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161212006088/en/
Contacts
Media
Didier Véron, +33 (0)1 58 33 51 16
Senior Vice-President, Public Affairs
and Communication
didier.veron@ipsen.com
or
Br igitte Le Guennec, +33 (0)1 58 33 51 17
Corporate External Communication Manager
brigitte.le.guennec@ipsen.com
or
Financial Community
Eugenia Litz, +44 (0) 1753 627721
Vice-President Investor Relations
eugenia.litz@ipsen.com
or
Cô me de La Tour du Pin, +33 (0)1 58 33 53 31
Investor Relations Manager
come.de.la.tour.du.pin@ipsen.com